• Analyst Divergence: UBS sets a modest $52.00 price target for CRISPR Therapeutics, while Citi's analyst projects a significantly higher $88.00, indicating varied outlooks on the gene-editing stock.
  • Casgevy's Potential: Citi's optimistic forecast is driven by anticipated strong demand for Casgevy, the FDA-approved sickle cell disease treatment, and upcoming updates on CRISPR Therapeutics' CTX310 program.
  • Positive Sentiment, Underperforming Stock: Despite a generally favorable average brokerage recommendation of 1.95 and recent FDA approval, CRISPR Therapeutics shares trade well below their early-2021 peak, presenting a potential investment opportunity.

UBS sets a $52.00 price target for CRISPR Therapeutics (NASDAQ: CRSP), 3.50% above its $50.22 share price when the target is posted. CRISPR Therapeutics develops gene-editing treatments, including Casgevy for sickle cell disease. A price target is an analyst’s estimate of where a stock may trade, offering insights into potential investment returns.

The UBS target suggests limited gains from $50.22. By comparison, Citi analyst Yigal Nochomovitz raises his target from $82.00 to $88.00 per share. The article cited by Citi describes that target as about 60% above its reference price. Using $50.22 instead, the $88.00 target represents about 75% upside, highlighting a more bullish CRISPR stock forecast.

Citi’s higher target reflects expectations of growing demand for Casgevy, which the FDA approves in late 2023. For that target to make sense, the treatment needs to bring in substantial revenue. Investors also await a key update on CRISPR Therapeutics’ CTX310 program before the end of 2026, as highlighted by The Motley Fool, further influencing the biotech stock's outlook.

Other analysts generally favor the stock, as highlighted by Zacks. Its average brokerage recommendation is 1.95 on a five-point scale, where 1 means Strong Buy. Of the 22 firms covering CRISPR Therapeutics, 11 rate it Strong Buy and one rates it Buy, indicating strong analyst ratings for the gene-editing pioneer.

CRISPR Therapeutics trades at $50.22, up $0.12, or 0.24%, with a 52-week range of $44.12 to $75.06. Despite Casgevy’s approval and the start of patient uptake, the shares remain well below their early-2021 peak, as highlighted by The Motley Fool, presenting a potential opportunity for investors in the gene therapy market.